Novel 1,4-benzothiazine derivatives as large conductance Ca 2+-activated potassium channel openers

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 5085-5092

  Calderone, Vincenzo ^b   Spogli, Roberto ^a   Martelli, Alma ^b   Manfroni, Giuseppe ^a   Testai, Lara ^b   Sabatini, Stefano ^a   Tabarrini, Oriana ^a   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 2 (3,5 DIBROMO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 BROMO 2 HYDROXYPHENYL) 4 METHYL 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 BROMO 2 HYDROXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 BROMO 2 METHOXYBENZYLIDENE) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 BROMO 2 METHOXYPHENYL) 4 METHYL 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 BROMO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE 1 OXIDE; 2 (5 BROMO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZINE 3(4H)THIONE; 2 (5 BROMO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTLHIAZIN 3(4H)ONE; 2 (5 BROMO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 3,4 DIHYDRO 2H 1,4 BENZOTHIAZINE; 2 (5 CHLORO 2 HYDROXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 (5 CHLORO 2 METHOXYPHENYL) 6 TRIFLUOROMETHYL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 2 [(5 BROMO 2 METHOXYPHENYL)HYDROXYMETHYL] 6 TRIFLUOROMETH YL 2H 1,4 BENZOTHIAZIN 3(4H)ONE; BENZOTHIAZEPINE DERIVATIVE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; MALE; NONHUMAN; RAT; VASCULAR RING; VASODILATATION;

ANIMALS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; THIAZINES; VASODILATION;

EID: 50249097212     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701605f     Document Type: Article

References (44)

1. Ca, a unique member of the voltage-gated K channel superfamily. News Physiol. Sci. 1998, 13, 112-117.
2. Vergara, C.; Latorre, R.; Marrion, N. V.; Adelman, J. P. Calcium-activated potassium channels. Curr. Opin. Neurobiol. 1998, 8, 321-329.
3. Rothberg, B. S. Allosteric modulation of ion channels: the case of Maxi-K. Sci. STKE 2004, 227, 16.
4. Ghatta, S.; Nimmagadda, D.; Xu, X.; O'Rourke, S. T. Large-conductance, calcium-activated potassium channels: Structural and functional implications. Pharmacol. Therapeut. 2006, 110, 103-116.
5. Faber, E. S. L.; Sah, P. Calcium-activated potassium channels: Multiple contributions to neuronal function. Neuroscientist 2003, 9, 181-194.
6. Berger, M. G.; Rusch, N. J. Voltage and calcium gated potassium channels: functional expression and therapeutic potential in the vasculature. Perspect. Drug Discovery 1999, 15, 313-332.
7. Barman, S. A.; White, R. E. BKCa channel modulation in pulmonary and coronary arterial smooth muscle. Recent Res. Dev. Physiol. 2004, 2 (Pt. I), 295-320.
8. Kume, H.; Mikawa, K.; Takagi, K.; Kotlikoff, M. I. Role of G-protein and KCa channels in the muscarinic and beta-adrenergic regulation of airway smooth muscle. Am. J. Physiol. 1995, 268, 221-230.
9. + channel. J. Biol. Chem. 2004, 279, 36746-36752.
10. Perez, G.; Toro, L. Differential modulation of large-conductance KCa channels by PKA in pregnant and nonpregnant myometrium. Am. J. Physiol. Cell. Physiol. 1994, 266, C1459-C1465.
11. Vogalis, F. Potassium channels in gastrointestinal smooth muscle. J. Auton. Pharmacol. 2000, 20, 207-213.
12. Atkinson, N. S.; Robertson, G. A.; Ganetzky, B. A component of calcium-activated potassium channels encoded by the Drosophila slo locus. Science 1991, 253, 551-555.
13. Bohm, R. A.; Wang, B.; Brenner, R.; Atkinson, N. S. Transcriptional control of Ca(2+)-activated K(+) channel expression: identification of a second, evolutionarily conserved, neuronal promoter. J. Exp. Biol. 2000, 203, 693-704.
14. + channel from smooth muscle. J. Biol. Chem. 1994, 269, 17274-17278.
15. + channels: a transmembrane beta-subunit homolog. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4137-4142.
16. Brenner, R.; Jegla, T. J.; Wickenden, A.; Liu, Y.; Aldrich, R. W. Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J. Biol. Chem. 2000, 275, 6453-6461.
17. + channel resistant to charybdotoxin and iberiotoxin. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5562-5567.
18. Lu, R.; Alioua, A.; Kumar, Y.; Eghbali, M.; Stefani, E.; Toro, L. MaxiK channel partners: Physiological impact. J. Physiol. 2006, 570, 65-72.
19. Starrett, J. E.; Dworetzky, S. I.; Gribkoff, V. K. Modulators of large-conductance calcium-activated potassium (BK) channels as potential therapeutic targets. Curr. Pharm. Des. 1996, 2, 413-428.
20. + channels: function, pharmacology and drugs. Curr. Med. Chem. 2002, 9, 1385-1395.
21. + channel modulators. In Voltage-Gated Ion Channels as Drug Targets; Methods and Principles in Medicinal Chemistry; Triggle, D. J., Gopalakrishnan, M., Rampe, D., Zheng, W., Eds.; Wiley-VCH: Weinheim, 2006; Vol. 29, pp 310-334.
22. Wu, S.-N.; Wu, A. Z.; Lin, M.-W. Pharmacological roles of the large-conductance calcium-activated potassium channel. Curr. Top. Med. Chem. 2006, 6, 1025-1030.
23. Lawson, K.; McKay, N. G. Modulation of potassium channels as a therapeutic approach. Curr. Pharm. Des. 2006, 12, 459-470.
24. Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress. J. Med. Chem. 2001, 44, 1627-1653.
25. Nardi, A.; Calderone, V.; Olesen, S.-P. Potassium channel openers: the case of BK channel activators. Lett. Drug Des. Discovery 2006, 3, 210-218.
26. Gribkoff, V. K.; Winquist, R. J. Voltage-gated cation channel modulators for the treatment of stroke. Expert Opin. Invest. Drugs 2005, 14, 579-592.
27. 1 subunit of the calcium-activated potassium channel. Trends Cardiovasc. Med. 2002, 12, 78-85.
28. Christ, G. J. K channels as molecular targets for the treatment of erectile dysfunction. J. Androl. 2002, 23, S10-S19.
29. Nardi, A.; Calderone, V.; Chericoni, S.; Morelli, I. Natural modulators of large-conductance calcium-activated potassium channels. Planta Med. 2003, 69, 885-892.
30. Olesen, S.-P.; Waetjen, F. Benzimidazole derivatives, their preparation and use. European Patent EP0477819 B1, 1992; Chem. Abstr. 1992, 117, 7924.
31. ATP-channel openers. J. Med. Chem. 2003, 46, 3670-3679; 2005, 48, 6766.
32. ATP- channel openers. Bioorg. Med. Chem. 2005, 13, 5581-5591.
33. Krapcho, J.; Szabo, A.; Williams, J. Synthesis of substituted 2-phenyl-1,4-benzothiaizn-3(4H)-ones and their activity as inhibitors of 1,4-dipyrrolidino-2-butyne. J. Med. Chem. 1963, 6, 214-216.
34. 2+-dependent large-conductance potassium channels: pharmacophore search and physiological evaluation of flavonoids. Bioorg. Med. Chem. Lett. 1997, 7, 759-762.
35. 2+-dependent large-conductance potassium channels: symmetrical pharmacophore and electrophysiological evaluation of bisphenols. Bioorg. Med. Chem. Lett. 2003, 13, 1437-1439.
36. Hemmi, K.; Neya, M.; Zenkoh, T.; Sawada, H.; Kasahara, C.; Murata, M. Preparation of acylamino acid analogs as endothelin antagonists. PCT Int. Appl. WO 9615109, 1996; Chem. Abstr. 1996, 125, 143304.
37. Coutts, R. T.; Barton, D. L.; Smith, E. M. Organic sulfur compounds II. Catalyzed sodium borohydride reductions of selected α-(o- nitrophenylthio)acids. Can. J. Chem. 1966, 44, 1733-1744.
38. Babudri, F.; Di Nunno, L.; Florio, S. Stereoselective synthesis of 2-alkylidene-3,4-dihydro-3-oxo-2H-1,4-benzothiazines. Tetrahedron 1982, 38, 3059-3065.
39. Babudri, F.; Florio, S.; Zuccaro, L. Stereoselective aldol condensation of 3,4-dihydro-3-oxo-2H-1,4-benzothiazines: X-ray determination of the aldol stereostructure. Tetrahedron 1985, 41, 569-573.
40. Sun, X. H.; Ding, J. P.; Li, H.; Pan, N.; Gan, L.; Yang, X. L.; Xu, H. B. Activation of large-conductance calcium-activated potassium channels by puerarin: the underlying mechanism of puerarin-mediated vasodilation. J. Pharmacol. Exp. Ther. 2007, 323, 391-397.
41. Unemoto, T.; Matsushita, M.; Tamura, K.; Tanaka, Y.; Koike, K.; Kogo, H. Role of BK channels in testosterone-induced relaxation of the aorta in spontaneously hypertensive rats. Biol. Pharm. Bull. 2007, 30, 1477-1480.
42. + channels and relaxes vascular smooth muscle. Eur. J. Pharmacol. 2007, 555, 185-193.
43. Saponara, S.; Testai, L.; Iozzi, D.; Martinotti, E.; Martelli, A.; Chericoni, S.; Sgaragli, G.; Fusi, F.; Calderone, V. (±)-Naringenin as large conductance Ca(2+)-activated K(+) (BK(Ca)) channel opener in vascular smooth muscle cells. Br. J. Pharmacol. 2006, 149, 1013-1021.
44. Hewawasam, P.; Meanwell, N. A.; Gribkoff, V. K. 3-Substituted oxindole derivatives as potassium channel modulators, and their preparation and therapeutic use thereof. U.S. Patent 5,602,169, 1997; Chem. Abstr. 1997, 126, 181369.